Amivantamab Plus Lazertinib in Patients With EGFR-mutant NSCLC by Benjamin Besse et al.
A recent article by Benjamin Besse et al. was mentioned by Akhil Santhosh, Medical Oncology Specialist at MVR Cancer Centre and Research Institute, on X:
“Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC).
After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A in Journal of Thoracic Oncology.”
Authors: Benjamin Besse, Koichi Goto, Yongsheng Wang, Se-Hoon Lee, Melina E. Marmarelis, Yuichiro Ohe, Reyes Bernabe Caro, Dong-Wan Kim, Jong-Seok Lee, Sophie Cousin, Eiki Ichihara, Yongsheng Li, Luis Paz-Ares, Akira Ono, Rachel E. Sanborn, Naohiro Watanabe, Maria Jose de Miguel, Carole Helissey, Catherine A. Shu, Alexander I. Spira, Pascale Tomasini, James Chih-Hsin Yang, Yiping Zhang, Enriqueta Felip Frank Griesinger, Saiama N. Waqar, Antonio Calles, Joel W. Neal, Christina S. Baik, Pasi A. Jänne, S. Martin Shreeve, Joshua C. Curtin, Bharvin Patel, Michael Gormley, Xuesong Lyu, Jun Chen, Pei-Ling Chu, Janine Mahoney, Leonardo Trani, Joshua M. Bauml, Meena Thayu, Roland E. Knoblauch and Byoung Chul Cho
More posts featuring Akhil Santhosh.
Benjamin Besse is the Head of Clinical Research at Gustave Roussy and a Full Professor of Medical Oncology at University of Paris-Saclay. He serves as the Chair of the Scientific Council at EORTC and is the Coordinator of RYTHMIC, the French thymic malignancies network.
His research is centered on personalized therapeutic strategies, focusing on molecular abnormalities, circulating biomarkers, and early drug development for thymic malignancies and thoracic tumors.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023